Diquafosol Tetrasodium

HCID 148196CAS 211427-08-6

부분 구조 검색 유사 구조 찾기

기본 정보

표준 SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OP(=O)([O-])OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1.[Na+].[Na+].[Na+].[Na+]
InChIKey: OWTGMPPCCUSXIP-FNXFGIETSA-J
분자식: C18H22N4Na4O23P4
평균 분자량: 878.2 g/mol

개요

See also: Diquafosol (has active moiety).

이름 및 식별자

우선 이름: Diquafosol Tetrasodium
IUPAC: tetrasodium;[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate
영어명: Diquafosol Tetrasodium
분자식: C18H27N4NaO23P4
분자량: 814.3

이름 및 동의어

Diquafosol tetrasodiumIns 365Diquafosol sodiumDiquafosol tetrasodium saltINS365X8T9SBH9LLKPY-998DE-089Diquafosol tetrasodium [USAN]Diquafosol sodium (JAN)UNII-X8T9SBH9LLDiquafosol tetrasodium (USAN)

이름 더 보기

D03864CID 9876095DiquafosoftetrasodiumDexamethoxol tetrasodiumDiquafosol Tetrasodium CRS

DIQUAFOSOL SODIUM [JAN]Uridine(5')tetraphospho(5')uridine tetrasodium saltDIQUAFOSOL TETRASODIUM [MART.]DIQUAFOSOL TETRASODIUM [WHO-DD]DIQUAFOSOL TETRASODIUM SALT [MI]P1,P4-Diuridine 5'-tetraphosphate tetrasodium saltDIQUAFOSOL TETRASODIUM (MART.)Uridine 5'-(pentahydrogen tetraphosphate), P'''-5'ester with uridine, tetrasodium salt

데이터베이스 식별자

CAS: 211427-08-6
PubChem CID: 148196
ChEMBL: CHEMBL1767408
UNII: X8T9SBH9LL

물성

구조 계산 물성

극성 표면적: 405 Å²
수소 결합 공여자 수: 6
수소 결합 수용자 수: 23
회전 가능 결합 수: 14
무거운 원자 수: 53
형식 전하: 0
복잡도: 1,460

물리화학적 성질

저장 조건: -20 °C · Store at -20°C
용해도: 1 · DMSO:1.0(Max Conc. mg/mL);1.14(Max Conc. mM)Water:100.0(Max Conc. mg/mL);113.86(Max Conc. mM)
물리적 상태: 고체
색상: White to off-white
수용성: 2 O: · H2O: 2mg/mL, clear
InChIKey: XPZQVLUPTGTIJP-NIBQMMLDNA-N

안전 및 규제

안전 데이터

wgk: WGK 3
스토리지 클래스: 11 - Combustible Solids

화학 및 산업

응용 분야 · 2건

개요Diquafosol (INS-365) was approved in Japan in 2010 as a 3% ophthalmic solution for treatment of dry eye disease. Clinical diagnosis of dry eye is difficult because the condition presents a variety of symptoms. Treatment options include tear supplements (lubricants), anti-inflammatory drugs (e.g., cyclosporine eye drops or steroid eye drops), and tear retention devices. Diquafosol is a unique agent for the treatment of dry eye in that it acts as a P2Y2 purinergic receptor agonist with the ability to activate this receptor on the ocular surface and stimulate water, lipid, and mucin secretion. Diquafosol is metabolized by phosphodiesterases to UTP, UDP, UMP, and uridine. Diquafosol has been well tolerated in clinical trials, with side effects being local to the ocular surface.In addition,no serious ocular or systemic adverse drug reactions were found during the clinical trials.

용도Enhancement of mucosal hydration in the treatment of chronic dry eye (P2Y2 receptor antagonist).

공급사50 곳

湖北威德利化学试剂有限公司181-6332-1995 18062128043 · [email protected]

济南百隆化学有限公司[email protected] · [email protected]

武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]

成都超九八生物科技有限公司13348960310 13348960310 · [email protected]

福建华耀医药科技有限公司18559985626 · [email protected]

연결된 노트

불러오는 중…